Skip to main content

Table 1 Patient characteristics

From: The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Variable

Value

 

Number

Percent

Age (years)

 Mean

65

 

 Range

34–87

 

Gender

 Male

78

54

 Female

66

46

Ethnicity

 Asian

1

1

 Caucasian

143

99

Smoking history

 Current smoker

49

34

 Former smoker

85

59

 Never smoker

10

7

ECOG performance statusa

 0

18

12

 1

80

56

 2

37

26

 3

9

6

Tumor type

 Adenocarcinoma

126

88

 Not otherwise specified (NOS)

9

6

 Adenosquamous carcinoma

5

3

 Large cell

3

2

 Adenocarcinoma in situ

1

1

Tumor stage

 IIIA+IIIB

5

3

 IV

139

97

Erlotinib therapy

 First-line

10

7

 Second-line

115

80

 Third-line

14

10

 Fourth-line

5

3

  1. aEastern Cooperative Oncology Group scale to assess how the disease affects the daily living abilities of the patient
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us